Is neutrophil gelatinase associated lipocalin useful in hepatitis C virus infection?

doi:10.4254/wjh.v8.i19.815

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 19

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7372)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-1) series.

Item

Count

PDF

480

WORD

272

HTML

2769

Figures (1-4)

156

Tables (1-1)

135

Sum=3812

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

351

Download

879

Sum=1230

Publishing Process of This Article

Item

Count

Browse

952

Download

1378

Sum=2330

Jul 8, 2016 (publication date) through Apr 29, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Hepatol. Jul 8, 2016; 8(19): 815-824
Published online Jul 8, 2016. doi: 10.4254/wjh.v8.i19.815

Full Size Figure Download Figure

Figure 4 Evolution of neutrophil gelatinase associated lipocalin (A) and estimated glomerular filtration rate (B) in 8 patients during the first 12 week of hepatitis C virus therapy with directly acting antiviral containing regimens. Number of patients and respective treatment for hepatitis C virus infection are specified. PEG-IFN: Pegylated-interferon; RBV: Ribavirin; TVR: Telaprevir, SMV: Simeprevir; DCV: Daclatasvir; eGFR: Estimated glomerular filtration rate; NGAL: Neutrophil gelatinase associated lipocalin.

Citation: Strazzulla A, Coppolino G, Di Fatta C, Giancotti F, D’Onofrio G, Postorino MC, Mazzitelli M, Mammone SV, Gentile I, Rivoli L, Palella E, Gravina T, Costa C, Pisani V, De Maria V, Barreca GS, Marascio N, Focà A, Fuiano G, Gulletta E, Torti C. Is neutrophil gelatinase associated lipocalin useful in hepatitis C virus infection? World J Hepatol 2016; 8(19): 815-824
URL: https://www.wjgnet.com/1948-5182/full/v8/i19/815.htm
DOI: https://dx.doi.org/10.4254/wjh.v8.i19.815